CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option
Go back to CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option| Merck & Co. (NYSE: MRK) | Delayed: 120.76 +1.67 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $119.09 | 52 Week High | $65.46 | |||
| Open | $120.04 | 52 Week Low | $47.97 | |||
| Day High | $122.71 | P/E | 82.15 | |||
| Day Low | $119.95 | EPS | $1.47 | |||
| Volume | 13,142,497 | |||||
